CareDx, Inc. (CDNA) COO Mitchell J. Nelles Sells 10,948 Shares
CareDx, Inc. (NASDAQ:CDNA) COO Mitchell J. Nelles sold 10,948 shares of CareDx stock in a transaction on Thursday, November 30th. The stock was sold at an average price of $7.17, for a total transaction of $78,497.16. Following the sale, the chief operating officer now directly owns 84,225 shares in the company, valued at approximately $603,893.25. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Shares of CareDx, Inc. (NASDAQ CDNA) traded up $0.12 during mid-day trading on Thursday, hitting $7.26. 143,649 shares of the stock traded hands, compared to its average volume of 356,003. The company has a debt-to-equity ratio of -124.53, a quick ratio of 0.35 and a current ratio of 0.55. CareDx, Inc. has a 1 year low of $0.76 and a 1 year high of $7.98.
CareDx (NASDAQ:CDNA) last announced its quarterly earnings results on Thursday, November 9th. The company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.02. The firm had revenue of $12.19 million for the quarter, compared to analysts’ expectations of $12.05 million. CareDx had a negative net margin of 84.14% and a negative return on equity of 157.00%. The company’s revenue was down 2.3% on a year-over-year basis. analysts forecast that CareDx, Inc. will post -0.83 earnings per share for the current year.
Several hedge funds have recently made changes to their positions in the company. Gagnon Securities LLC boosted its position in shares of CareDx by 3.9% during the 3rd quarter. Gagnon Securities LLC now owns 2,166,403 shares of the company’s stock valued at $8,016,000 after acquiring an additional 82,111 shares during the last quarter. Royce & Associates LP boosted its position in shares of CareDx by 8.1% during the 3rd quarter. Royce & Associates LP now owns 792,787 shares of the company’s stock valued at $2,933,000 after acquiring an additional 59,500 shares during the last quarter. Private Wealth Partners LLC boosted its position in shares of CareDx by 2,250.0% during the 3rd quarter. Private Wealth Partners LLC now owns 235,000 shares of the company’s stock valued at $869,000 after acquiring an additional 225,000 shares during the last quarter. Thompson Davis & CO. Inc. boosted its position in shares of CareDx by 3,294.9% during the 3rd quarter. Thompson Davis & CO. Inc. now owns 203,692 shares of the company’s stock valued at $754,000 after acquiring an additional 197,692 shares during the last quarter. Finally, Stonepine Capital Management LLC acquired a new position in shares of CareDx during the 2nd quarter valued at about $212,000. 23.15% of the stock is currently owned by hedge funds and other institutional investors.
CareDx Company Profile
CareDx, Inc is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company’s commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection.
Receive News & Ratings for CareDx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx Inc. and related companies with MarketBeat.com's FREE daily email newsletter.